Biosafety of Molecular Farming in Genetically Modified Plants

  • Didier Breyer
  • Adinda De Schrijver
  • Martine Goossens
  • Katia Pauwels
  • Philippe Herman


The use of genetically modified plants for large-scale production of recombinant compounds for pharmaceutical or industrial use, known as plant molecular farming, holds several promises. However, any development in this field must be counterbalanced by a thorough evaluation of risks to human health and the environment. The possible impact of accidental contamination of the food and feed chain or of transgene spread in the environment, in particular when major food/feed crops grown in open fields are involved, highlights the need to carefully address some important issues during the safety assessment of genetically modified farming plants, such as the choice of the production platform, the implementation of containment or confinement measures and the adoption of other relevant management strategies. In this chapter, we report on the applicability of the current risk assessment methodology and principles, outline some important issues linked to the assessment of environmental and health risks, and comment in more detail general management strategies that could be applied to limit potential environmental and human health impacts linked to plant molecular farming.


European Union Genetically Modify European Food Safety Authority Genetically Modify Plant Molecular Farming 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahmad A, Pereira EO, Conley AJ, Richman AS, Menassa R (2010) Green biofactories: recombinant protein production in plants. Recent Pat Biotechnol 4(3):242–259CrossRefGoogle Scholar
  2. Alderborn A, Sundström J, Soeria-Atmadja D, Sandberg M, Andersson HC, Hammerling U (2010) Genetically modified plants for non-food or non-feed purposes: straightforward screening for their appearance in food and feed. Food Chem Toxicol 48(2):453–464CrossRefGoogle Scholar
  3. Basaran P, Rodríguez-Cerezo E (2008) Plant molecular farming: opportunities and challenges. Crit Rev Biotechnol 28(3):153–172CrossRefGoogle Scholar
  4. Becker G, Vogt D (2005) Regulation of plant-based pharmaceuticals. CRS report for congress. Order Code RS21418, March 8Google Scholar
  5. Breyer D, Goossens M, Herman P, Sneyers M (2009) Biosafety considerations associated with molecular farming in genetically modified plants. J Med Plant Res 3(11):825–838Google Scholar
  6. CFIA (2004a) Directive 94–08. Assessment criteria for determining environmental safety of plants with novel traits. Accessed 28 Feb 2011
  7. CFIA (2004b) Directive Dir2000-07: conducting confined research field trials of plant with novel traits in Canada. Accessed 28 Feb 2011
  8. Codex (2003) Codex Alimentarius Commission 2003 (ALINORM 03/34A). Guideline for the conduct of food safety assessment of foods derived from recombinant DNA plants. Annex on the assessment of possible allergenicity, Rome, Italy. Codex Alimentarius Commission, YokohamaGoogle Scholar
  9. Commandeur U, Twyman RM, Fischer R (2003) The biosafety of molecular farming in plants. AgBiotechNet 5:1–9Google Scholar
  10. Corrado G, Karali M (2009) Inducible gene expression systems and plant biotechnology. Biotechnol Adv 27:733–743CrossRefGoogle Scholar
  11. Daniell H (2002) Molecular strategies for gene containment in transgenic corps. Nat Biotechnol 20:581–586CrossRefGoogle Scholar
  12. de Maagd RA, Boutilier K (2009) Efficacy of strategies for biological containment of transgenic crops. Plant Research International B.V., WageningenGoogle Scholar
  13. Dunwell JM, Ford CS (2005) Technologies for biological containment of GM and non-GM crops. Defra contract CPEC 47. Final report. Accessed 28 Feb 2011
  14. EC (2001) Council Directive 2001/18/EC of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Off J Eur Union L106:1–38Google Scholar
  15. EC (2003) Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed. Off J Eur Union L268:1–23Google Scholar
  16. EC (2004) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J Eur Union L136:1–33Google Scholar
  17. EC (2006) Commission Regulation (EC) No 2023/2006 of 22 December 2006 on good manufacturing practice for materials and articles intended to come into contact with food. Off J Eur Union L384:75–78Google Scholar
  18. EC (2009) Directive 2009/41/EC of the European Parliament and of the Council of 6 May 2009 on the contained use of genetically modified micro-organisms. Off J Eur Union L125:75–97Google Scholar
  19. EFSA (2006) Guidance document of the scientific panel on genetically modified organisms for the risk assessment of genetically modified plants and derived food and feed. EFSA J 99:1–100Google Scholar
  20. EFSA (2009) EFSA scientific panel on Genetically Modified Organisms (GMO); Scientific opinion on guidance for the risk assessment of genetically modified plants used for non-food or non-feed purposes, on request of EFSA. EFSA Journal 1164. [42 pp.]. Available online
  21. EFSA (2010) EFSA scientific panel on Genetically Modified Organisms (GMO); guidance on the environmental risk assessment of genetically modified plants. EFSA Journal 8(11):1879. [111 pp.]. doi: 10.2903/j.efsa.2010.1879. Available online Google Scholar
  22. FDA (2002) Draft guidance for industry. Drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals. Accessed 28 Feb 2011
  23. Federal Register Notice (2003) 68 FR 11337–11340. Accessed 28 Feb 2011
  24. Fox JL (2003) Puzzling industry response to prodigene fiasco. Nat Biotechnol 21:3–4CrossRefGoogle Scholar
  25. Franconi R, Costantina O, Demurtas OC, Massa S (2010) Plant-derived vaccines and other therapeutics produced in contained systems. Expert Rev Vaccines 9(8):877–892CrossRefGoogle Scholar
  26. Goldstein DA, Thomas JA (2004) Biopharmaceuticals derived from genetically modified plants. QJM 97:705–716CrossRefGoogle Scholar
  27. Gressel J, Valverde BE (2009) A strategy to provide long-term control of weedy rice while mitigating herbicide resistance transgene flow, and its potential use for other crops with related weeds. Pest Manag Sci 65:723–731CrossRefGoogle Scholar
  28. Hennegan K, Yang DC, Nguyen D, Wu LY, Goding J, Huang JM, Guo FL, Huang N, Watkins S (2005) Improvement of human lysozyme expression in transgenic rice grain by combining wheat (Triticum aestivum) puroindoline b and rice (Oryza sativa) Gt1 promoters and signal peptides. Transgenic Res 14:583–592CrossRefGoogle Scholar
  29. Hills MJ, Hall L, Arnison PG, Good AG (2007) Genetic use restriction technologies (GURTs): strategies to impede transgene movement. Trends Plant Sci 12:177–183CrossRefGoogle Scholar
  30. Howard JA, Hood EE (2007) Methods for growing nonfood products in transgenic plants. Crop Sci 47:1255–1262CrossRefGoogle Scholar
  31. Hüsken A, Prescher S, Schiemann J (2010) Evaluating biological containment strategies for pollen-mediated gene flow. Environ Biosafety Res. doi: 10.1051/ebr/2010009
  32. Kobayashi K, Munemura I, Hinata K, Yamamura S (2006) Bisexual sterility conferred by the differential expression of barnase and barstar: a simple and efficient method of transgene containment. Plant Cell Rep 25:1347–1354CrossRefGoogle Scholar
  33. Komarova TV, Baschieri S, Donini M, Marusic C, Benvenuto E, Dorokhov YL (2010) Transient expression systems for plant-derived biopharmaceuticals. Expert Rev Vaccines 9(8):859–876CrossRefGoogle Scholar
  34. Lau OS, Sun SS (2009) Plant seeds as bioreactors for recombinant protein production. Biotechnol Adv 27(6):1015–1022CrossRefGoogle Scholar
  35. Liénard D, Sourrouille C, Gomord V, Faye L (2007) Pharming and transgenic plants. Biotechnol Annu Rev 13:115–147CrossRefGoogle Scholar
  36. Mascia PN, Flavell RB (2004) Safe and acceptable strategies for producing foreign molecules in plants. Curr Opin Plant Biol 7:189–195CrossRefGoogle Scholar
  37. Meyers B, Zaltsman A, Lacroix B, Kozlovsky SV, Krichevsky A (2010) Nuclear and plastid genetic engineering of plants: comparison of opportunities and challenges. Biotechnol Adv 28:747–756. doi: 10.1016/j.biotechadv.2010.05.022 CrossRefGoogle Scholar
  38. Moon HS, Li Y, Stewart CN Jr (2010) Keeping the genie in the bottle: transgene biocontainment by excision in pollen. Trends Biotechnol 28(1):3–8CrossRefGoogle Scholar
  39. Moschini G (2006) Pharmaceutical and industrial traits in genetically modified crops: co-existence with conventional agriculture. Working paper 06-WP 429. Center for Agricultural and Rural DevelopmentGoogle Scholar
  40. Murphy DJ (2007) Improving containment strategies in biopharming. Plant Biotechnol J 5:555–569CrossRefGoogle Scholar
  41. NARA (2005) Introductions of plants genetically engineered to produce industrial compounds. Fed Regist USA 70(85):23009–23011Google Scholar
  42. Obembe OO, Popoola JO, Leelavathi S, Reddy SV (2010) Advances in plant molecular farming. Biotechnol Adv. doi: 10.1016/j.biotechadv.2010.11.004
  43. Peterson RKD, Arntzen CJ (2004) On risk and plant-based biopharmaceuticals. Trends Biotechnol 22:64–66CrossRefGoogle Scholar
  44. Plasson C, Michel R, Lienard D, Saint-Jore-Dupas C, Sourrouille C, de March GG, Gomord V (2009) Production of recombinant proteins in suspension-cultured plant cells. Methods Mol Biol 483:145–161CrossRefGoogle Scholar
  45. Pogue GP, Vojdani F, Palmer KE, Hiatt E et al (2010) Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 8(5):638–654CrossRefGoogle Scholar
  46. Ramessar K, Sabalza M, Capell T, Christou P (2008) Maize plants: an ideal production platform for effective and safe molecular pharming. Plant Sci 174:409–419CrossRefGoogle Scholar
  47. Rehbinder E, Engelhard M, Hagen K, Jørgensen RB, Pardo Avellaneda R, Schnieke A, Thiele F (2009) Pharming. Promises and risks of biopharmaceuticals derived from genetically modified plants and animals. Ethics of science and technology assessment, Vol 35. Springer, p 334. ISBN: 978-3-540-85792-1Google Scholar
  48. Ruf S, Karcher D, Bock R (2007) Determining the transgene containment level provided by chloroplast transformation. Proc Natl Acad Sci USA 104(17):6998–7002CrossRefGoogle Scholar
  49. SCBD (2000) Secretariat of the convention on biological diversity. Cartagena protocol on biosafety to the convention on biological diversity: text and annexes. Secretariat of the Convention on Biological Diversity, MontrealGoogle Scholar
  50. Shama LM, Peterson RKD (2008a) Assessing risks of plant-based pharmaceuticals: I. Human dietary exposure. Hum Ecol Risk Assess 14:179–193CrossRefGoogle Scholar
  51. Shama LM, Peterson RKD (2008b) Assessing risks of plant-based pharmaceuticals: II. Non-target organism exposure. Hum Ecol Risk Assess 14:194–204CrossRefGoogle Scholar
  52. Sparrow PA, Twyman RM (2009) Biosafety, risk assessment and regulation of plant-made pharmaceuticals. Methods Mol Biol 483:341–353CrossRefGoogle Scholar
  53. Sparrow PA, Irwin JA, Dale PJ, Twyman RM, Ma JK (2007) Pharma-Planta: road testing the develo­ping regulatory guidelines for plant-made pharmaceuticals. Transgenic Res 16(2):147–161CrossRefGoogle Scholar
  54. Spök A (2007) Molecular farming on the rise – GMO regulators still walking a tightrope. Trends Biotechnol 25:74–82CrossRefGoogle Scholar
  55. Spök A, Karner S (2008) Plant molecular farming: opportunities and challenges. European commission, joint research centre, institute for prospective technological studiesGoogle Scholar
  56. Spök A, Twyman RM, Fischer R, Ma JKC, Sparrow PAC (2008) Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends Biotechnol 646:1–12Google Scholar
  57. Streatfield SJ, Lane JR, Brooks CA, Barker DK, Poage ML, Mayor JM, Lamphear BJ, Drees CF, Jilka JM, Hood EE, Howard JA (2003) Corn as a production system for human and animal vaccines. Vaccine 21:812–815CrossRefGoogle Scholar
  58. Union of Concerned Scientists (2006) UCS position paper: pharmaceutical and industrial crops. UCS. Accessed 28 Feb 2011
  59. USDA (2006) Permitting genetically engineered plants that produce pharmaceutical compounds. BRS factsheet. Accessed 28 Feb 2011
  60. USDA (2008) Guidance for APHIS permits for field testing or movement of organisms intended for pharmaceutical or industrial use. Accessed 28 Feb 2011
  61. Vancanneyt G, Dubald M, Schröder W, Peters J, Botterman J (2009) A case study for plant-made pharmaceuticals comparing different plant expression and production systems. Methods Mol Biol 483:209–221CrossRefGoogle Scholar
  62. Verma D, Daniell H (2007) Chloroplast vector systems for biotechnology applications. Plant Physiol 145:1129–1143CrossRefGoogle Scholar
  63. WHO (2003) WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Accessed 28 Feb 2011
  64. Wolt JD, Karaman S, Wang K (2007) Risk assessment for plant-made pharmaceuticals. CAB Rev Perspect Agric Vet Sci Nutr Nat Resour 2(12):1–9Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Didier Breyer
    • 1
  • Adinda De Schrijver
    • 1
  • Martine Goossens
    • 1
  • Katia Pauwels
    • 1
  • Philippe Herman
    • 1
  1. 1.Biosafety and Biotechnology UnitScientific Institute of Public HealthBrusselsBelgium

Personalised recommendations